Literature DB >> 23607283

Morphometric and functional changes of salivary gland dysfunction after radioactive iodine ablation in a murine model.

Jeong-Seok Choi1, In Suh Park, Seok-Ki Kim, Jae-Yol Lim, Young-Mo Kim.   

Abstract

BACKGROUND: Ablation of the thyroid tissue using radioactive iodine (RAI) after the surgical removal of well-differentiated thyroid cancer can induce radiation-related salivary gland (SG) dysfunction. However, in vivo changes of SGs after RAI administration in appropriate animal models are not well described in the literature. This study was undertaken to document morphometric and functional changes during the 12 months after RAI administration in a murine model of RAI-induced SG dysfunction.
METHODS: Four-week-old female C57BL/6 mice (n = 60) were divided into an RAI-treated group (n = 30) that received RAI orally (0.01 mCi/g body weight) and an unexposed control group (n = 30). Mice in both groups were divided into five subgroups (n = 6 per subgroup) and euthanized at 1, 2, 3, 6, and 12 months post-RAI administration. Salivary flow rates and salivary lag times were measured at 1, 2, 3, 6, and 12 months after RAI administration. Morphological and histological examinations and terminal deoxynucleotidyl transferase dUTP nick end labeling assays were performed. In addition, changes in salivary (99m)Tc pertechnetate uptake and excretion were observed by single-photon emission computed tomography.
RESULTS: In RAI-treated mice, the SGs were significantly lighter than those of unexposed controls at all study time points. Lag times to salivation in the RAI-treated group were greater than in the unexposed controls, but mean salivary flow rates were lower. Histologic examinations of SGs in the RAI group showed pale cytoplasm, atypical ductal configuration, septal widening, cytoplasmic vacuolization with pleomorphism, lymphocyte infiltration, and increased fibrosis. Furthermore, more apoptotic cells were observed in acini and ducts in the RAI group. In addition, patterns of (99m)Tc pertechnetate uptake and excretion in the RAI group were quite different from those observed in controls at 1 and 12 months post-RAI.
CONCLUSION: Various histological alterations were observed in mice exposed to RAI, that is, an increase in apoptotic acini and ductal cells and functional SG deterioration. The murine model of RAI-induced SG dysfunction used in the present study appears to be applicable to preclinical research on RAI-induced sialadenitis in patients with well-differentiated thyroid cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23607283      PMCID: PMC3822387          DOI: 10.1089/thy.2012.0243

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  24 in total

1.  Analysis of human sodium iodide symporter immunoreactivity in human exocrine glands.

Authors:  C Spitzweg; W Joba; K Schriever; J R Goellner; J C Morris; A E Heufelder
Journal:  J Clin Endocrinol Metab       Date:  1999-11       Impact factor: 5.958

Review 2.  The sodium iodide symporter: its emerging relevance to clinical thyroidology.

Authors:  C Spitzweg; A E Heufelder
Journal:  Eur J Endocrinol       Date:  1998-04       Impact factor: 6.664

3.  99mTc-pertechnetate uptake in parotid acinar cells by the Na+/K+/Cl- co-transport system.

Authors:  J Helman; R J Turner; P C Fox; B J Baum
Journal:  J Clin Invest       Date:  1987-05       Impact factor: 14.808

4.  Distribution and dynamics of (99m)Tc-pertechnetate uptake in the thyroid and other organs assessed by single-photon emission computed tomography in living mice.

Authors:  Philippe R Franken; Julien Guglielmi; Christian Vanhove; Malick Koulibaly; Michel Defrise; Jacques Darcourt; Thierry Pourcher
Journal:  Thyroid       Date:  2010-05       Impact factor: 6.568

5.  Salivary gland protection by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (amifostine) in high-dose radioiodine treatment: results obtained in a rabbit animal model and in a double-blind multi-arm trial.

Authors:  K H Bohuslavizki; S Klutmann; L Jenicke; S Kröger; R Buchert; J Mester; M Clausen
Journal:  Cancer Biother Radiopharm       Date:  1999-10       Impact factor: 3.099

6.  Evaluation and characterization of congenital hypothyroidism in rdw dwarf rats.

Authors:  M Umezu; S Kagabu; J Jiang; E Sato
Journal:  Lab Anim Sci       Date:  1998-10

7.  [Quantitative salivary gland scintigraphy--a recommended examination prior to and after radioiodine therapy].

Authors:  K H Bohuslavizki; W Brenner; S Lassmann; S Tinnemeyer; S Kalina; M Clausen; E Henze
Journal:  Nuklearmedizin       Date:  1997-04       Impact factor: 1.379

8.  The dental safety profile of high-dose radioiodine therapy for thyroid cancer: long-term results of a longitudinal cohort study.

Authors:  Martin A Walter; Christian P Turtschi; Christian Schindler; Peter Minnig; Jan Müller-Brand; Beat Müller
Journal:  J Nucl Med       Date:  2007-09-14       Impact factor: 10.057

9.  Sialochemical and oxidative analyses in radioactive I131-treated patients with thyroid carcinoma.

Authors:  Sophia Ish-Shalom; Lena Durleshter; Elena Segal; Rafael M Nagler
Journal:  Eur J Endocrinol       Date:  2008-05       Impact factor: 6.664

Review 10.  The Na+/I- symporter (NIS): recent advances.

Authors:  O Levy; A De la Vieja; N Carrasco
Journal:  J Bioenerg Biomembr       Date:  1998-04       Impact factor: 2.945

View more
  7 in total

1.  Murine Salivary Functional Assessment via Pilocarpine Stimulation Following Fractionated Radiation.

Authors:  Jomy J Varghese; Isaac L Schmale; Mollie Eva Hansen; Shawn D Newlands; Danielle S W Benoit; Catherine E Ovitt
Journal:  J Vis Exp       Date:  2018-05-04       Impact factor: 1.355

2.  Establishment of an Effective Radioiodide Thyroid Ablation Protocol in Mice.

Authors:  Kathrin A Schmohl; Andrea M Müller; Nathalie Schwenk; Kerstin Knoop; Eddy Rijntjes; Josef Köhrle; Heike Heuer; Peter Bartenstein; Burkhard Göke; Peter J Nelson; Christine Spitzweg
Journal:  Eur Thyroid J       Date:  2015-05-23

3.  MnTnBuOE-2-PyP treatment protects from radioactive iodine (I-131) treatment-related side effects in thyroid cancer.

Authors:  Anery Patel; Elizabeth A Kosmacek; Kurt W Fisher; Whitney Goldner; Rebecca E Oberley-Deegan
Journal:  Radiat Environ Biophys       Date:  2019-11-14       Impact factor: 1.925

Review 4.  Sialadenitis as a complication of radioiodine therapy in patients with thyroid cancer: where do we stand?

Authors:  Marios Adramerinas; Dimitrios Andreadis; Konstantinos Vahtsevanos; Athanasios Poulopoulos; Kalliopi Pazaitou-Panayiotou
Journal:  Hormones (Athens)       Date:  2021-06-18       Impact factor: 2.885

5.  Radioprotective Effect of Epigallocatechin-3-Gallate on Salivary Gland Dysfunction After Radioiodine Ablation in a Murine Model.

Authors:  Jeong-Seok Choi; Hye-Young An; In Suh Park; Seok-Ki Kim; Young-Mo Kim; Jae-Yol Lim
Journal:  Clin Exp Otorhinolaryngol       Date:  2016-05-03       Impact factor: 3.372

6.  Anti-inflammatory and vasculogenic conditioning of peripheral blood mononuclear cells reinforces their therapeutic potential for radiation-injured salivary glands.

Authors:  Takashi I; Yoshinori Sumita; Takako Yoshida; Ryo Honma; Mayumi Iwatake; Jorge Luis Montenegro Raudales; Tomoko Shizuno; Shinichiro Kuroshima; Haruchika Masuda; Makoto Seki; Simon D Tran; Takayuki Asahara; Izumi Asahina
Journal:  Stem Cell Res Ther       Date:  2019-10-17       Impact factor: 6.832

7.  Fucoidan attenuates radioiodine-induced salivary gland dysfunction in mice.

Authors:  Young-Mo Kim; Jeong Mi Kim; Ji Won Kim; Mi Eun Choi; Seok-Ki Kim; Jeong-Seok Choi
Journal:  BMC Oral Health       Date:  2019-08-30       Impact factor: 2.757

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.